Specialty Pharmaceutical Company
Curatis is a specialty pharmaceutical company based in Switzerland. We focus on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases.
Our Strategy
Curatis identifies potential drug candidates in indications with high unmet medical need via its extensive network within the scientific and medical community and the biotech/pharmaceutical industry.
Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization. All of Curatis' development projects have been selected in line with this strategy.
For our distribution business, Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland, with expansion into Germany, France, the UK, and Italy.
Board of Directors
Dr. Marian Borovsky
Chairman, Non-Executive Member of the Board of Directors
As Group General Counsel and a member of the Executive Committee, led Actelion's legal department for 17 years from its startup phase until its acquisition by Johnson & Johnson in 2017. Thereafter, held interim positions as Group General Counsel/Chief Legal Officer with Idorsia Pharmaceuticals AG (March – October 2022) and at Swiss Rockets AG/Rocketvax AG (May – July 2021). Mr. Borovsky holds a doctorate in law, is an attorney-at-law and a qualified business mediator.
Günter Graubach
Founder & Executive Member of the Board of Directors, Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012–April 2024) and Curatis' Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a Maîtrise Administration Économique et Sociale from the University of Lyon, France and a lic.oec.int in International Economic Relations from the University of Constance, Germany.
Dr. Roland Rutschmann
Executive Member of the Board of Directors, Chief Executive Officer (CEO)
Board member of Curatis AG and former Chief Executive Officer of Curatis (2012–2019). Previously held positions as Vice President/General Manager at Orphan Europe in Paris and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.
Dr. Silvio Inderbitzin
Non-Executive Member of the Board of Directors
Member of the Board of Directors and shareholder of Curatis. Has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his background in pharmaceutical manufacturing, he served as Head of Quality Assurance and was responsible for product release as a Qualified Person at Spirig Pharma AG. Was elected Technical Director and served in the Corporate Management Team, ultimately joining the board of directors and becoming co-owner of the privately held 450-employee company. Prior to the sale of Spirig Pharma AG, he served as CEO and was responsible for its foreign subsidiaries. Active investor and board member of several life science and MedTech companies and startups. Studied pharmacy at the University of Berne, holds a Ph.D. in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.
Executive Management
Dr. Roland Rutschmann
Chief Executive Officer (CEO)
Former board member of Curatis AG (since 2010) and Chief Executive Officer of Curatis AG (2011–2019). Previously held positions as Vice President/General Manager at Orphan Europe in Paris and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.
Günter Graubach
Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012–April 2024) and Curatis' Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a Master's Degree in Business from the University of Lyon, France and a post graduate degree in Economics from the University of Constance, Germany.
François Bersier
Chief Operating Officer (COO)
Former Chief Executive Officer at Curatis AG (2019–April 2024). Previously General Manager at Alexion Pharma International (GmbH), held various commercial & marketing management lead positions at Roche Pharma, Sanofi-Aventis and Caris Life Sciences. More than 25 years of experience in the Life Sciences & Biotechnology industry at national and international levels (Germany, France, Austria, Greece, Israel, Republic of South Africa). Focus on (ultra) rare diseases & oncology. Expertise in strategic & operational marketing, market access and P&R. Educated as a pharmacist, holds a Master's Degree in Marketing, graduated from INSEAD Marketing Champions Program.
Patrick Ramsauer
Chief Financial Officer (CFO)
CFO of Curatis and a member of the executive management team. Previously held various positions in Corporate Finance at UBS AG and as Founder and Portfolio Manager in RBR Capital, a Swiss Asset Management company, as well as in the technology sector with Palantir, a US-based AI and data integration software company. Also CFO of a data integration company and Partner in Yuma Capital, a Swiss corporate finance advisory boutique. More than 25 years of experience in finance, and holds a degree in Finance from the University of Zurich.
Advisory Board
Stewart Goldman, MD
Pediatric Oncology
Internationally renowned pediatric oncologist, Chair of the Department of Child Health at the University of Arizona College of Medicine, Phoenix, Senior Vice President of Research at Phoenix Children's and Sybil B Harrington Endowed Chair of Oncology. He oversees a research program of over 700 studies. Previously served 23 years at Ann and Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine as Division Head of Hematology-Oncology, Neuro-Oncology and Stem Cell Transplantation. Has published more than 170 peer-reviewed articles. MD from Loyola University Stritch School of Medicine.
Prof. Dr. med. Andreas Gantenbein
Neurology & Headache
Started his career as clinical research fellow in the Headache Group of Peter Goadsby at Queen Square, London, focusing on electrophysiological correlates in migraine. From 2010–2012 head of the Headache and Pain Unit at the University Hospital of Zurich. From 2012 continued research and clinical work at RehaClinic Bad Zurzach, serving as Chief Physician of Neurology until 2021. Former president of the Swiss Headache Society. Research focus includes medication overuse headache, menstrual migraine, and CGRP-antibodies. Has published more than 100 articles in peer-reviewed journals.
Dr. Anthony Man
Drug Development
B.Med Sci, MB, BS, FRCP (UK). Originally trained in internal medicine and oncology; currently serves as independent consultant in drug development to Biotechnology companies and NGOs in Global Health. Over 35 years of experience in international clinical research through all clinical stages from IND to Life Cycle Management across oncology, infectious disease, rheumatology, metabolic disease, cardiovascular, and transplantation medicine. Has contributed to over 30 successful new drug applications. Previously held senior roles at Lederle, Roche, Ciba Geigy and Novartis. Served 2000–2013 as Chief Development Officer and CEO of Basilea Pharmaceutica.
Prof. Dr. Arnim Pause
Biochemistry
M.Sc., Ph.D. Professor of Biochemistry at McGill University's Goodman Cancer Institute and the Department of Biochemistry in Montreal (2002–present). Also Senior Director of Research at Kreamedica Inc. Scientific Advisor at Curatis AG (2010–present). Author of over 90 high-impact peer-reviewed publications, book chapters, and patents. Previously held leadership roles at Boehringer Ingelheim and the Max-Planck Institute for Biochemistry. Ph.D. in Biochemistry from McGill University; Fogarty/DFG fellowship at the National Cancer Institute (NCI), USA. Research expertise spans cancer biology, virology, and metabolic diseases.